Profund Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $523K | Sell |
2,766
-105
| -4% | -$18.4K | 0.02% | 536 |
|
|
2025
Q4 | $488K | Sell |
2,871
-806
| -22% | -$124K | 0.01% | 576 |
|
|
2025
Q3 | $485K | Sell |
3,677
-838
| -19% | -$101K | 0.02% | 524 |
|
|
2025
Q2 | $479K | Buy |
4,515
+358
| +9% | +$38.9K | 0.02% | 473 |
|
|
2025
Q1 | $516K | Sell |
4,157
-514
| -11% | -$67.1K | 0.02% | 458 |
|
|
2024
Q4 | $575K | Sell |
4,671
-1,164
| -20% | -$137K | 0.02% | 439 |
|
|
2024
Q3 | $650K | Buy |
5,835
+110
| +2% | +$12.1K | 0.02% | 432 |
|
|
2024
Q2 | $611K | Sell |
5,725
-1,559
| -21% | -$171K | 0.02% | 436 |
|
|
2024
Q1 | $877K | Buy |
7,284
+1,074
| +17% | +$132K | 0.03% | 393 |
|
|
2023
Q4 | $764K | Buy |
6,210
+141
| +2% | +$17.6K | 0.03% | 395 |
|
|
2023
Q3 | $786K | Sell |
6,069
-688
| -10% | -$91.7K | 0.04% | 342 |
|
|
2023
Q2 | $838K | Buy |
6,757
+282
| +4% | +$37.9K | 0.04% | 359 |
|
|
2023
Q1 | $947K | Sell |
6,475
-532
| -8% | -$78.7K | 0.06% | 314 |
|
|
2022
Q4 | $1.12M | Buy |
7,007
+165
| +2% | +$24.2K | 0.07% | 245 |
|
|
2022
Q3 | $912K | Sell |
6,842
-596
| -8% | -$90.6K | 0.07% | 262 |
|
|
2022
Q2 | $1.16M | Sell |
7,438
-572
| -7% | -$88.1K | 0.07% | 233 |
|
|
2022
Q1 | $1.25M | Buy |
8,010
+628
| +9% | +$91.1K | 0.05% | 273 |
|
|
2021
Q4 | $940K | Sell |
7,382
-232
| -3% | -$30.5K | 0.03% | 352 |
|
|
2021
Q3 | $991K | Sell |
7,614
-740
| -9% | -$112K | 0.03% | 355 |
|
|
2021
Q2 | $1.48M | Buy |
8,354
+912
| +12% | +$158K | 0.05% | 272 |
|
|
2021
Q1 | $1.22M | Sell |
7,442
-1,376
| -16% | -$226K | 0.05% | 267 |
|
|
2020
Q4 | $1.46M | Buy |
8,818
+729
| +9% | +$109K | 0.06% | 242 |
|
|
2020
Q3 | $1.15M | Buy |
8,089
+2,959
| +58% | +$367K | 0.06% | 255 |
|
|
2020
Q2 | $566K | Buy |
5,130
+457
| +10% | +$50.5K | 0.03% | 379 |
|
|
2020
Q1 | $466K | Sell |
4,673
-42
| -0.9% | -$5.43K | 0.04% | 383 |
|
|
2019
Q4 | $704K | Buy |
4,715
+544
| +13% | +$74K | 0.03% | 462 |
|
|
2019
Q3 | $534K | Sell |
4,171
-948
| -19% | -$127K | 0.03% | 567 |
|
|
2019
Q2 | $730K | Sell |
5,119
-585
| -10% | -$78.6K | 0.03% | 477 |
|
|
2019
Q1 | $815K | Buy |
5,704
+951
| +20% | +$124K | 0.04% | 421 |
|
|
2018
Q4 | $589K | Sell |
4,753
-1,009
| -18% | -$150K | 0.04% | 408 |
|
|
2018
Q3 | $969K | Buy |
5,762
+3,838
| +199% | +$660K | 0.04% | 408 |
|
|
2018
Q2 | $332K | Sell |
1,924
-96
| -5% | -$15.7K | 0.01% | 1094 |
|
|
2018
Q1 | $305K | Sell |
2,020
-174
| -8% | -$25.5K | 0.01% | 1133 |
|
|
2017
Q4 | $295K | Sell |
2,194
-862
| -28% | -$120K | 0.01% | 1140 |
|
|
2017
Q3 | $447K | Buy |
3,056
+141
| +5% | +$21.3K | 0.02% | 841 |
|
|
2017
Q2 | $453K | Buy |
2,915
+38
| +1% | +$5.81K | 0.02% | 809 |
|
|
2017
Q1 | $418K | Buy |
2,877
+296
| +11% | +$38.6K | 0.02% | 964 |
|
|
2016
Q4 | $281K | Sell |
2,581
-550
| -18% | -$61.3K | 0.01% | 1269 |
|
|
2016
Q3 | $380K | Sell |
3,131
-44
| -1% | -$5.93K | 0.02% | 944 |
|
|
2016
Q2 | $449K | Sell |
3,175
-267
| -8% | -$39.4K | 0.02% | 871 |
|
|
2016
Q1 | $449K | Sell |
3,442
-1,134
| -25% | -$141K | 0.02% | 810 |
|
|
2015
Q4 | $643K | Sell |
4,576
-434
| -9% | -$60.1K | 0.03% | 544 |
|
|
2015
Q3 | $665K | Sell |
5,010
-1,365
| -21% | -$235K | 0.04% | 419 |
|
|
2015
Q2 | $1.12M | Buy |
6,375
+276
| +5% | +$49.6K | 0.05% | 358 |
|
|
2015
Q1 | $1.05M | Buy |
6,099
+343
| +6% | +$58.9K | 0.04% | 468 |
|
|
2014
Q4 | $942K | Buy |
5,756
+600
| +12% | +$99.6K | 0.04% | 474 |
|
|
2014
Q3 | $828K | Buy |
5,156
+1,688
| +49% | +$260K | 0.04% | 456 |
|
|
2014
Q2 | $510K | Sell |
3,468
-182
| -5% | -$25.2K | 0.02% | 897 |
|
|
2014
Q1 | $506K | Buy |
3,650
+641
| +21% | +$96.5K | 0.02% | 869 |
|
|
2013
Q4 | $381K | Buy |
3,009
+137
| +5% | +$14.2K | 0.02% | 1224 |
|
|
2013
Q3 | $264K | Buy |
+2,872
| New | +$232K | 0.01% | 1368 |
|
Other funds holding JAZZ
VPM
VCM
EC
Profund Advisors's JAZZ Position: Q1 2026 in Review
Profund Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 3.7% in Q1 2026, selling an estimated $18.4K and leaving 2,766 shares worth $523K. The position accounts for 0.02% of the portfolio, ranked #536.
Profund Advisors first reported a position in JAZZ in Q3 2013 and has held it in 51 quarters since. The position peaked at $1.48M in Q2 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Profund Advisors held 2,766 shares of Jazz Pharmaceuticals worth $523K as of Q1 2026.
- Profund Advisors sold 105 Jazz Pharmaceuticals shares in Q1 2026, an estimated $18.4K.
- Jazz Pharmaceuticals made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #536 holding.
- Profund Advisors first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
- Profund Advisors's Jazz Pharmaceuticals position peaked at $1.48M in Q2 2021.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.